Creating a “VALUE” added position

Eyeing strategic deals in India has been the major focus of the global pharma companies who are stepping their feet in India particularly Pfizer and Glaxo.

Pfizer has gone south in establishing licensing cum marketing deal for its 30-40 products in 2009. Further, Glaxo last year has had strategic stake investment in Dr. Reddy laboratories. This deal gave the UK drug giant exclusive access to the latter's portfolio and future pipeline comprising more than 100 branded pharmaceuticals across areas such as diabetes, cancer and pain management, in emerging markets. In July 2008, the firm linked up with South Africa's Aspen and its Indian joint venture partner Strides Arcolabs to sell branded generics in emerging markets.

This blog is co-posted with the Veeda Clinical Research Blog.